Economic burden of cancer across the European Union: a population-based cost analysis

Luengo-Fernández, Ramón; Leal, José; Gray, Alastair; Sullivan, Richard

doi:10.1016/s1470-2045(13)70442-x

Cited by 818 publications

(740 citation statements)

References 14 publications

Supporting

Mentioning

674

Contrasting

Unclassified

Order By: Relevance

“…In the Netherlands, official data on costs for lung cancer, CHD, stroke and COPD were available 23. Costs of smoking‐related diseases were obtained from the literature in Germany 24, 25, 26, 27 and Spain 28, 29, 30, 31, 32. Further details are found in country‐specific technical annexes 16, 17, 18, 19, 20.…”

Section: Methodsmentioning

confidence: 99%

Estimates of costs for modelling return on investment from smoking cessation interventions

Trapero-Bertran

Leidl²,

Muñoz

et al. 2018

Addiction

View full text Add to dashboard Cite

Background and aimsModelling return on investment (ROI) from smoking cessation interventions requires estimates of their costs and benefits. This paper describes a standardized method developed to source both economic costs of tobacco smoking and costs of implementing cessation interventions for a Europe‐wide ROI model [European study on Quantifying Utility of Investment in Protection from Tobacco model (EQUIPTMOD)].DesignFocused search of administrative and published data. A standardized checklist was developed in order to ensure consistency in methods of data collection.Setting and participantsAdult population (15+ years) in Hungary, Netherlands, Germany, Spain and England. For passive smoking‐related costs, child population (0–15 years) was also included.MeasurementsCosts of treating smoking‐attributable diseases; productivity losses due to smoking‐attributable absenteeism; and costs of implementing smoking cessation interventions.FindingsAnnual costs (per case) of treating smoking attributable lung cancer were between €5074 (Hungary) and €52 106 (Germany); coronary heart disease between €1521 (Spain) and €3955 (Netherlands); chronic obstructive pulmonary disease between €1280 (England) and €4199 (Spain); stroke between €1829 (Hungary) and €14 880 (Netherlands). Costs (per recipient) of smoking cessation medications were estimated to be: for standard duration of varenicline between €225 (England) and €465 (Hungary); for bupropion between €25 (Hungary) and €220 (Germany). Costs (per recipient) of providing behavioural support were also wide‐ranging: one‐to‐one behavioural support between €34 (Hungary) and €474 (Netherlands); and group‐based behavioural support between €12 (Hungary) and €257 (Germany). The costs (per recipient) of delivering brief physician advice were: €24 (England); €9 (Germany); €4 (Hungary); €33 (Netherlands); and €27 (Spain).ConclusionsCosts of treating smoking‐attributable diseases as well as the costs of implementing smoking cessation interventions vary substantially across Hungary, Netherlands, Germany, Spain and England. Estimates for the costs of these diseases and interventions can contribute to return on investment estimates in support of national or regional policy decisions.

show abstract

Section: Methodsmentioning

confidence: 99%

Estimates of costs for modelling return on investment from smoking cessation interventions

Trapero-Bertran

Leidl²,

Muñoz

et al. 2018

Addiction

View full text Add to dashboard Cite

show abstract

“…For each country, the annual health‐care costs for an individual with each of the diseases were estimated based on a systematic literature review 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55. Costs relate to prevalent cases of disease.…”

Section: Methodsmentioning

confidence: 99%

Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation

Coyle

Lester‐George

et al. 2017

Addiction

View full text Add to dashboard Cite

Background and AimsAlthough clear benefits are associated with reducing smoking, there is increasing pressure on public health providers to justify investment in tobacco control measures. Decision‐makers need tools to assess the Return on Investment (ROI)/cost‐effectiveness of programmes. The EQUIPT project adapted an ROI tool for England to four European countries (Germany, the Netherlands, Spain and Hungary). EQUIPTMOD, the economic model at the core of the ROI tool, is designed to assess the efficiency of packages of smoking cessation interventions. The objective of this paper is to describe the methods for EQUIPTMOD and identify key outcomes associated with continued and cessation of smoking.MethodsEQUIPTMOD uses a Markov model to estimate life‐time costs, quality‐adjusted life years (QALYs) and life years associated with a current and former smoker. It uses population data on smoking prevalence, disease prevalence, mortality and the impact of smoking combined with associated costs and utility effects of disease. To illustrate the tool's potential, costs, QALYs and life expectancy were estimated for the average current smoker for five countries based on the assumptions that they continue and that they cease smoking over the next 12 months. Costs and effects were discounted at country‐specific rates.ResultsFor illustration, over a life‐time horizon, not quitting smoking within the next 12 months in England will reduce life expectancy by 0.66, reduce QALYs by 1.09 and result in £4961 higher disease‐related health care costs than if the smoker ceased smoking in the next 12 months. For all age–sex categories, costs were lower and QALYs higher for those who quit smoking in the 12 months than those who continued.ConclusionsEQUIPTMOD facilitates assessment of the cost effectiveness of smoking cessation strategies. The demonstrated results indicate large potential benefits from smoking cessation at both an individual and population level.

show abstract

“…Adatok forrásai: incidencia -Országos Onkológiai Intézet Nemzeti Rákregiszter [6]; mortalitás -WHO Mortalitási Adatbázis [7]; népességi adatok -KSH Statisztikai Adatbázis [8] Az elmúlt 20 évben a költségek emelkedéséhez hozzájá-rult a PSA-szűrés miatti túldiagnosztizálások számának radikális emelkedése [9]. 2009-ben az Európai Unió 27 országában az összes daganatos betegség gazdasági terhe, a direkt és az indirekt költségeket is fi gyelembe véve, 126 milliárd euró volt, amelynek 44%-áért a tüdőrák, a vastagbélrák, az emlőrák és a prosztatarák felelős [10]. A 126 milliárd euró-ból Magyarország részesedése 980 millió euró, amely egy lakosra számolva átlagosan 39 eurót jelent, és ebből 5 euróért a prosztatarák tehető felelőssé [10].…”

Section: -2009unclassified

The economic burden of prostate cancer. A systematic literature overview of registry-based studies

et al. 2014

View full text Add to dashboard Cite

Bevezetés: A prosztatarák a férfi ak leggyakoribb malignus megbetegedése Európában, amelynek a társadalmi terhe is jelentős. Célkitűzés: Az elmúlt 10 évben megjelent, regisztereken alapuló, prosztatarák betegségterhével foglalkozó közlemények szisztematikus áttekintése és a betegséghez kapcsolódó költségeket meghatározó tényezők elemzése. Módszer: A szerzők Medline-keresést végeztek angol nyelvű folyóiratokban a 2003. január 1. és 2013. október 1. közötti időszakra. Eredmények: Tizenöt peer-reviewed folyóiratban megjelent közlemény került beválogatásra. A fejlett országokban a legnagyobb költségtétel a sugárkezelés, a sebészi kezelés és a hormonális terápia volt. Az egy betegre jutó éves terápiás költség Európában a korai stádiumú (4-7 ezer €, 2006), az Egyesült Államokban pedig a metasztatikus prosztatarák (19,9-25,5 ezer $, 2004) esetén volt magasabb. A terápiás fázisok szempontjából Euró-pában a kezdeti terápia (6,4 ezer €/6 hónap, 2008), az Egyesült Államokban pedig a végstádium (életkortól füg-gően: 62,2-93,4 ezer $, 2010) egy betegre jutó éves költségei voltak magasabbak. Következtetések: Viszonylag kevés szakirodalom áll rendelkezésre a prosztatarák betegségterhével kapcsolatosan Európában. Egyre növekvő népegész-ségügyi jelentősége ellenére hazánkban nem rendelkezünk ilyen adatokkal. Orv. Hetil., 2014, 155(13), 509-520.

show abstract

Economic burden of cancer across the European Union: a population-based cost analysis

Cited by 818 publications

References 14 publications

Estimates of costs for modelling return on investment from smoking cessation interventions

Estimates of costs for modelling return on investment from smoking cessation interventions

Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation

The economic burden of prostate cancer. A systematic literature overview of registry-based studies

Contact Info

Product

Resources

About